Unlocking better growth for CDMOs

The contract development and manufacturing organization (CDMO) industry is rapidly evolving, with the emergence of new modalities, breakthrough innovations in existing therapeutic areas, regulatory changes, and increasing demand for personalized medicine. These changes offer CDMOs ample opportunities to drive growth – but a one-size-fits-all approach to offering, pricing, and quoting will fail. To capitalize on these opportunities, CDMOs must adopt differentiated commercial strategies to unlock better growth.

With a CAGR of seven percent, the CDMO segment is expected to grow to a 160-billion-dollar market by 2025. Not surprising, as the market is primed for growth.

Key drivers of this growth are manifold and include emerging modalities such as cell and gene therapy and ADCs,…